Administration

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, April 15, 2024
Sale, Idiopathic pulmonary fibrosis, Weill Cornell Medicine, University, Internal, Research and development, Epithelium, Investment, Fibroblast, Interstitial, Pleural effusion, IPF, LPE, Intensive care medicine, Administration, University of Giessen, University of Alabama, Patient, Acquisition, Fibrosis, Associate, Series, Therapy, G&A, Critical Care Medicine (journal), ALRN, Pharmaceutical industry

AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”, the “Company”, “we”, “our” or “us”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • We expect to report topline results from the ongoing Phase 1b study of LTI-03 in the third quarter of this year.
  • Net Loss: Net loss for the quarter ended December 31, 2023, was $7.3 million, compared to $4.5 million for the quarter ended December 31, 2022.
  • The basic and diluted net loss per share for the quarter ended December 31, 2023 was $1.54 compared to $1.00 for the quarter ended December 31, 2022.
  • The basic and diluted net loss per share for the full-year 2023 was $3.42 compared to $6.02 for the full-year 2022.

SBA Statement on Biden-Harris Administration Exceeding Small Disadvantaged Business Contracting Goal

Retrieved on: 
Friday, April 12, 2024
CHIPS, Science, Administration, Small business, Holocene, Development aid, Category management, SBA, Federal, Human, Federation, Policy, Senior, Acquisition, KEGG, Participation, Pharmaceutical industry

In January 2024, the Biden-Harris Administration announced a bold goal of increasing the share of federal contracting dollars going to SDBs to 15% by FY2025, a 50% increase from spending levels when he first took office.

Key Points: 
  • In January 2024, the Biden-Harris Administration announced a bold goal of increasing the share of federal contracting dollars going to SDBs to 15% by FY2025, a 50% increase from spending levels when he first took office.
  • As part of President Biden’s agenda , the SBA has announced new and improved initiatives to advance this goal – and we’re already seeing results.
  • “Today’s announcement shows the results, with a new record of contract spending with Small Disadvantaged Businesses and steady progress towards President Biden’s goal of awarding 15% of federal contracting dollars to Small Disadvantaged Businesses by FY2025.
  • The new procedures increase contracting opportunities for 8(a)-certified SDBs to ensure more equitable access to federal contracting dollars.

KULR Technology Group Reports Record Annual Revenue for 2023

Retrieved on: 
Friday, April 12, 2024
CubeSat, Transport, Safety, Depreciation, CAE Inc., Research, KULR, Administration, Pratt & Whitney, TRS, South, Electronics, Lockheed Martin, Special, Spacecraft, Recycling, SAN, Cryptocurrency

SAN DIEGO, April 12, 2024 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a global leader in sustainable energy management, today announced its financial results for full-year 2023.

Key Points: 
  • SAN DIEGO, April 12, 2024 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a global leader in sustainable energy management, today announced its financial results for full-year 2023.
  • The increase in revenue was mainly due to early success in the energy storage and battery transportation and recycling sectors.
  • Selling, General and Administrative (SG&A) Expenses: SG&A expenses increased to $19,882,402 in 2023 from $16,453,776 in 2022.
  • Revenue has grown at a compound annual growth rate of 102% from 2021 through 2023.

Virco Reports Full Year Revenue Increased 16.5% to $269.1 million, delivering 32.4% growth in Net Income

Retrieved on: 
Friday, April 12, 2024
VIRC, School, Management, Forward, Growth, History, Administration, Tax, Optimism, NOL

Net revenue for the full year ended January 31, 2024 increased 16.5% to $269.1 million from $231.1 million in the prior year.

Key Points: 
  • Net revenue for the full year ended January 31, 2024 increased 16.5% to $269.1 million from $231.1 million in the prior year.
  • For the seasonally light fourth quarter, revenue increased 9.8% to $42.6 million from $38.8 million.
  • Operating Income for the full year ended January 31, 2024 was $31.9 million compared to $10.6 million the prior year.
  • Total Net Income after taxes for the full year was $21.9 million compared to $16.5 million the prior year.

Utz Brands Reports First Quarter 2024 Results

Retrieved on: 
Thursday, May 2, 2024
Food, Beverage, Retail, Sale, Table, Investment, Depreciation, Utz Brands, Capital expenditure, Administration, EPS, Marketing, Adjustment, Good, IOS, GAAP, Growth, Bookkeeping

First quarter net sales were $346.5 million compared to $351.4 million in the prior year period.

Key Points: 
  • First quarter net sales were $346.5 million compared to $351.4 million in the prior year period.
  • The Company’s total Power Brands’ retail sales increased 4.9% versus the prior-year period(1) and the Company’s Power Four Brands of Utz®, On The Border®, Zapp’s® and Boulder Canyon® increased 6.0%.
  • (1) Circana Total US MULO-C, custom Utz Brands hierarchy, on a pro forma basis.
  • Adjusted Net Income in the quarter increased 38.7% to $20.8 million compared to $15.0 million in the prior year period.

Superior Reports First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 2, 2024
Other Manufacturing, Aftermarket, Automotive, Engineering, Tires & Rubber, Automotive Manufacturing, General Automotive, Manufacturing, Net income, Appendix, Administration, Development, Public expenditure, Debt, Foreign exchange market, Aluminium, SPG, LTM, GAAP, Operation, Income tax, Bank

We expect Superior to exit 2024 as a business generating approximately $190 million of Adjusted EBITDA on unit sales of just over 15 million,” commented Majdi Abulaban, President and Chief Executive Officer of Superior.

Key Points: 
  • We expect Superior to exit 2024 as a business generating approximately $190 million of Adjusted EBITDA on unit sales of just over 15 million,” commented Majdi Abulaban, President and Chief Executive Officer of Superior.
  • Income from Operations was $0.3 million in the first quarter of 2024, compared to Income from Operations of $15 million in the first quarter of 2023.
  • Income Tax Provision for the first quarter of 2024 was $17 million, compared to an Income Tax Provision of $3 million in the first quarter of 2023.
  • Adjusted EBITDA, a Non-GAAP financial measure, was $31 million, or 18% of Value-Added Sales in the first quarter of 2024, which compares to $46 million, or 22% of Value-Added Sales, in the first quarter of 2023.

Kontoor Brands Reports 2024 First Quarter Results; Raises Full Year Outlook

Retrieved on: 
Thursday, May 2, 2024
Fashion, Online Retail, Retail, Manufacturing, Specialty, Textiles, Internet, DTC, International, Kontoor Brands, POS, Investment, Growth, Expense, Forecasting, Capital expenditure, Administration, KTB, Environment, EPS, Ratio, Line of credit, Share repurchase, GAAP, Lee, Wrangler, Natural gas

Kontoor Brands, Inc. (NYSE: KTB), a global lifestyle apparel company, with a portfolio led by two of the world’s most iconic consumer brands, Wrangler® and Lee®, today reported financial results for its first quarter ended March 30, 2024.

Key Points: 
  • Kontoor Brands, Inc. (NYSE: KTB), a global lifestyle apparel company, with a portfolio led by two of the world’s most iconic consumer brands, Wrangler® and Lee®, today reported financial results for its first quarter ended March 30, 2024.
  • “Our first quarter results were stronger than expected, driven by higher revenue, gross margin, and cash flow,” said Scott Baxter, President, Chief Executive Officer and Chair of Kontoor Brands.
  • “We are pleased with another quarter of market share gains and the improvement we saw in POS and retailer inventories over the course of the first quarter.
  • Kontoor Brands will host its first quarter 2024 conference call beginning at 8:30 a.m. Eastern Time today, May 2, 2024.

Rev. Al Sharpton Demands Diversity on Delaware’s Chancery Court

Retrieved on: 
Tuesday, April 30, 2024
Professional Services, Courts, Public Policy, Government, DEI (Diversity, Equity and Inclusion), State, Local, Advocacy Group Opinion, Well, DEI, Administration, Son, Governor Carney, City, Woman, Human, Black, Court, Circuit court, Court of Chancery, Judiciary, Multimedia

Reverend Al Sharpton gave the keynote address, stating: “We look at the National Climate where people have declared war on DEI (diversity, equity and inclusion).

Key Points: 
  • Reverend Al Sharpton gave the keynote address, stating: “We look at the National Climate where people have declared war on DEI (diversity, equity and inclusion).
  • One of the Sons of this State, President Joe Biden has said, ‘we must have diversity’.
  • 70% of his appointments to the Circuit Court have been people of color, 78% [have been] women, and 40% Black women.
  • I was sent to the Chancery Court when I was being sued by the Governor and Lt Governor for protesting.

MorphoSys AG Reports First Quarter 2024 Financial Results

Retrieved on: 
Monday, April 29, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Sale, FDA, Bone marrow, BET, Research and development, EDT, Investment, Safety, JAK, Food, EZH1, Research, Marketing, EZH2, Administration, ASCO, Novartis, Ruxolitinib, Patient, Supervisory board, Society, Acquisition, Operating cost, Annual general meeting, G&A, European Medicines Agency

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.
  • The financial results presented for the first quarter of 2024 relate to continuing business operations of MorphoSys.
  • Full Year 2024 Financial Guidance:
    As a consequence of the sale and transfer of tafasitamab to Incyte on February 5, 2024, MorphoSys' 2024 financial guidance published on January 30, 2024, cannot be maintained and therefore was revoked.
  • MorphoSys Group Key Figures (IFRS, end of the first quarter: March 31, 2024)

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, April 10, 2024
Abele, AAAAI, FDA, Citizenship, Research, Healthcare Improvement Scotland, Trial of the century, SMC, IND, Record, Intellectual property, National Congress, American Academy, Attack, Food, ACAAI, Conference, Hereditary angioedema, MHRA, HAE, Therapy, Network, EOP, Book, PRO, Chemistry, CMC, G&A, Investigational New Drug, Doctor of Philosophy, Medication, Research and development, American College, Mass meeting, Health care, Administration, Bank statement, Annual general meeting, Heredity, Pharmaceutical industry

Pharvaris is currently enrolling in RAPIDe-3, a global pivotal Phase 3 study of deucrictibant immediate-release capsule (PHVS416) for the on-demand treatment of HAE attacks.

Key Points: 
  • Pharvaris is currently enrolling in RAPIDe-3, a global pivotal Phase 3 study of deucrictibant immediate-release capsule (PHVS416) for the on-demand treatment of HAE attacks.
  • Effective April 15, 2024, David Nassif, J.D., will join Pharvaris as Chief Financial Officer and will be responsible for refining and implementing Pharvaris’ corporate financial strategy and activities including financial reporting and operations.
  • Loss for the fourth quarter of 2023 was €32.7 million, resulting in basic and diluted loss per share of €0.74.
  • Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.